Literature DB >> 21257300

Hepatitis B virus infection, its sequelae, and prevention by vaccination.

Li-Min Huang1, Chun-Yi Lu, Ding-Shinn Chen.   

Abstract

Hepatitis B virus (HBV) infection is a global health problem. There are >350 million of people chronically infected with this virus worldwide. Hepatitis B vaccines are effective in preventing the infection. Humoral immunity is the key factor in conferring the protection. Hepatitis B surface antibody titers of ≥10mIU/mL are protective. Chronic carriage of HBV is related to the age when the infection occurs, the younger the age the higher the chronicity rate. Hence, vaccination should be given in early childhood. People vaccinated in infancy have a protection of >20 years, and hepatocellular carcinoma decreases in them. Although the vaccine-conferred immunity wanes by time, a universal booster is not recommended at present.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21257300     DOI: 10.1016/j.coi.2010.12.013

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  19 in total

1.  NKT cells--an early warning system for HBV infection.

Authors:  Dale I Godfrey; Adam P Uldrich; Alan G Baxter
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

2.  Results of continuous monitoring of the performance of rubella virus IgG and hepatitis B virus surface antibody assays using trueness controls in a multicenter trial.

Authors:  Tamara Kruk; Sam Ratnam; Jutta Preiksaitis; Allan Lau; Todd Hatchette; Greg Horsman; Paul Van Caeseele; Brian Timmons; Graham Tipples
Journal:  Clin Vaccine Immunol       Date:  2012-08-15

Review 3.  NKT cells in liver diseases.

Authors:  Shasha Zhu; Huimin Zhang; Li Bai
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

Review 4.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

5.  Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.

Authors:  Hong Shi; Lu Lu; Ning-Ping Zhang; Shun-Cai Zhang; Xi-Zhong Shen
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

Review 6.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

7.  The future of cancer research: prevention, screening, vaccines, and tumor-specific drug combos.

Authors:  George Blanck
Journal:  Hum Vaccin Immunother       Date:  2013-12-17       Impact factor: 3.452

8.  Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic HBV infected patients.

Authors:  Yanling Zhu; Bo Qin; Chunyan Xiao; Xi Lu; Limin Chen
Journal:  Dig Dis Sci       Date:  2012-05-15       Impact factor: 3.199

Review 9.  Vaccines for immunoprevention of cancer.

Authors:  Tomohiro Enokida; Alvaro Moreira; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

10.  Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome.

Authors:  Francisco Rodriguez-Frías; David Tabernero; Josep Quer; Juan I Esteban; Israel Ortega; Esteban Domingo; Maria Cubero; Sílvia Camós; Carles Ferrer-Costa; Alex Sánchez; Rosendo Jardí; Melanie Schaper; Maria Homs; Damir Garcia-Cehic; Jaume Guardia; Rafael Esteban; Maria Buti
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.